Novo setback casts doubt on a new way to treat heart disease
BioPharma Dive
Ziltivekimab's failure in a key trial hurt spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
pharminent
July 31, 2026 (Last updated: August 3, 2026)
BioPharma Dive
Ziltivekimab’s failure in a key trial hurt spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
